Compare IZEA & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | BDSX |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.8M | 62.5M |
| IPO Year | N/A | 2020 |
| Metric | IZEA | BDSX |
|---|---|---|
| Price | $4.41 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 58.7K | ★ 72.0K |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $36,176,492.00 | ★ $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | $15.91 | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.12 | ★ 22.29 |
| 52 Week Low | $1.68 | $3.44 |
| 52 Week High | $5.86 | $31.00 |
| Indicator | IZEA | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 33.47 |
| Support Level | $4.30 | $6.55 |
| Resistance Level | $4.74 | $6.92 |
| Average True Range (ATR) | 0.17 | 0.54 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 16.67 | 15.56 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.